secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001821586-25-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3
--------------------------------------------------------------------------------

- Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.
- R&D expenses rose to $112.8M in 2024 from $31.8M in 2023 as Phase 3 trials for HS and PsA started.
- Cash and equivalents of $448.0M as of Dec 31, 2024, down from $493.9M in Q3 2024; runway to end of 2026.
- Initiated Phase 3 VELA (HS), Phase 3 IZAR (PsA), plus Phase 2 trials in PPP, axSpA, and adolescent HS.
- Capital Markets Update planned for Q2 2025 to discuss Phase 3 HS data and financials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/0001821586-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/mnlk-20250226.htm
  HTML page:      https://secwatch.observer/filing/0001821586-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer